The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant
NCT ID: NCT02967055
Last Updated: 2020-08-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
9 participants
OBSERVATIONAL
2017-02-15
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antepartum Etonogestrel Contraceptive Implant Insertion at Term
NCT03656289
Etonogestrel Implant as Emergency Contraception
NCT05237141
An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment
NCT01466673
Effectiveness of Prolonged Use of IUD/Implant for Contraception
NCT02267616
Postpartum Etonogestrel Implant for Adolescents
NCT01666912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have at least two negative pregnancy tests at least 19 days apart prior to initiating isotretinoin therapy
* Have normal baseline laboratory evaluation including liver function tests, basic metabolic panel, and complete blood count
* Willing to abstain from taking any Vitamin A supplement during the study period
* Have a Body Mass Index (BMI) \>= 18.5
Exclusion Criteria
* Known contraindications to isotretinoin
* Currently taking any known cytochrome P-450 3A4 enzyme inducers or inhibitors
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Society of Family Planning
OTHER
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aaron Lazorwitz, MD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Denver
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-0614
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.